Media release: SMC decisions July 2025

Posted on:

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, July 07) published advice on eight medicines.

Selpercatinib (Retsevmo®) was accepted for the treatment of patients, 12 years and older, with thyroid cancer that is advanced and caused by mutations in a gene called RET.

Pembrolizumab (Keytruda®) was accepted, used together with chemotherapy for the first-line treatment of adults with advanced endometrial cancer which is newly diagnosed or has come back after treatment. 

Abaloparatide (Eladynos®) was accepted for the treatment of osteoporosis in postmenopausal patients at increased risk of fracture.

Osimertinib (Tagrisso®) was accepted, used together with chemotherapy for the first-line treatment of adults with non-small cell lung cancer that is advanced, where the cancer cells have mutations in exon 19 or exon 21 of the EGFR gene.

Amivantamab (Rybrevant®) used together with chemotherapy was not recommended for the treatment of adults with non-small cell lung cancer that is advanced, where the cancer cells have certain mutations in exon 20 of the EGFR gene.

Fezolinetant (Veoza®) was not recommended for the treatment of moderate to severe vasomotor symptoms due to the menopause. Vasomotor symptoms include hot flushes and night sweats.

Lecanemab (Leqembi®) was not recommended to treat the early stages of Alzheimer’s disease in adults who carry one or no copies of a gene called ApoE4.

Bevacizumab gamma (Lytenava®) was accepted for the treatment of adults with the wet form of age-related macular degeneration.

Quote / Testimonial:
“The committee is pleased to be able to accept these new medicines for use by NHSScotland.

Selpercatinib offers an oral targeted treatment that can be taken at home for this small group of patients with advanced thyroid cancer that is driven by a RET mutation.
“Pembrolizumab used together with chemotherapy offers some patients with advanced endometrial cancer the chance of an immunotherapy treatment option at first-line who would otherwise not have it.

Osimertinib used together with chemotherapy offers the potential to delay the progression of disease in patients with certain types of advanced non-small cell lung cancer.

However, the committee was unable to accept amivantamab for the treatment of certain types of advanced non-small cell lung cancer as the company’s evidence around the cost effectiveness of the treatment, compared to currently available options, was not sufficient.

SMC welcomed the resubmission for lecanemab and recognises the need for new therapies for Alzheimer’s disease. However, having considered all the evidence, the committee was still unable to accept lecanemab for use in the NHS in Scotland. They felt that there remains uncertainty around what the modest clinical benefit means for patients and their families, and, in addition, the cost-effective estimates supplied by the company were too high.“The committee was also unable to accept fezolinetant for treating vasomotor symptoms due to the menopause as the company’s evidence around the cost-effectiveness of the treatment was not sufficient.

For the medicines we were unable to accept we would welcome a resubmission from the companies addressing the issues we have raised.”
Dr Scott Muir
SMC chair

Notes to editor

  1. The Scottish Medicines Consortium (SMC) is the national source of advice on the clinical and cost-effectiveness of all new medicines for NHSScotland. Our aim is to ensure that people in Scotland have timely access to beneficial new medicines.
  2. We are part of Healthcare Improvement Scotland. Our committee is made up of clinicians, pharmacists, NHS board representatives, the pharmaceutical industry and the public. Most of the clinicians have a direct role in patient care, while our three volunteer public partners ensure the views of the Scottish public are taken into account during decision making. This wide mixture of backgrounds ensures decisions are made from a broad perspective.
  3. Members of the SMC Committee make their decisions based on a broad range of evidence in order to help health professionals deliver the best possible care within the finite resources available. They consider detailed evidence presented by pharmaceutical companies, patient groups and clinicians in order to decide which medicines provide value for money for NHSScotland.
  4. When we talk about value for money or cost effectiveness, this does not just mean how much a medicine costs to buy, but the wider costs and benefits associated with it being regularly used to treat those with a particular condition. The NHS does not have unlimited resources and if we accept a medicine where the benefits are not clear it may mean other patients lose out.
  5. When considering a new medicine we look at:
  • whether it is good value for money.
  • how well the medicine works
  • which patients with the particular condition would benefit from it
  • whether it is as good as or better than the medicines already used to treat the particular condition, and
  • whether it is good value for money.

For more information on how we make our decisions, go to the SMC website, https://www.scottishmedicines.org.uk/how-we-decide/

  1. Changes to the way we assess medicines for end of life and rare conditions (https://www.scottishmedicines.org.uk/how-we-decide/pace/) have allowed our committee additional flexibility in decision making. These changes include the option of a Patient and Clinician Engagement (PACE) meeting which gives patient groups and clinicians the opportunity to provide additional evidence to the committee.
  2. A new approach to the assessment of medicines which treat extremely rare conditions has been introduced (https://www.scottishmedicines.org.uk/how-we-decide/ultra-orphan-medicines-for-extremely-rare-conditions/) in line with the Scottish Government announcement in June 2018 on a new pathway (https://news.gov.scot/news/treatments-for-rare-conditions)
  3. SMC can make the following decisions on a medicine:
  • accepted
  • accepted with a restriction(s) (for example, the medicine can only be accepted in a particular group of patients with the condition. This typically occurs because the company has requested this explicitly in the submission)
  • accepted on an interim basis, or
  • not recommended

SMC can accept some medicines on an interim basis subject to ongoing evaluation and reassessment. You can find out more about this on our website https://www.scottishmedicines.org.uk/how-we-decide/interim-acceptance-decision-option/

SMC may be unable to accept a medicine for use in Scotland if the committee is not satisfied that the benefits of the medicine offer value for money for patients and the NHS or where there is a high degree of uncertainty about the clinical benefits of the medicine. You can find out more about the reasons we may not recommend medicines on our website: https://www.scottishmedicines.org.uk/how-we-decide/

  1. For medicines that have not been recommended, SMC welcomes a resubmission from the company at any time with new clinical and/or economic evidence.
  2. When a medicine has not been recommended by SMC, all NHS boards have procedures in place to consider individual requests when a doctor feels the medicine would be right for a particular patient.
  3. For further information and to view the complete advice for the medicines detailed above, visit our website at: www.scottishmedicines.org.uk.
  4. For further information on ILAP, please visit the MHRA website https://www.gov.uk/guidance/innovative-licensing-and-access-pathway